THE EXPERIENCE OF THE USE OF ALLOKINE-ALPHA IN TREATMENT OF CHRONIC PERSISTING VIRAL MIXT-INFECTIONS IN MEN

  • Юрий Заседа д. м. н. Главный врач клиники «Мужское Здоровье» г. Киев
  • Руслан Соломенный врач-уролог клиники «Мужское Здоровье» г. Киев
  • Фарид Шихалиев врач-уролог клиники «Мужское Здоровье» г. Киев
Keywords: viral infections, prostatitis, immunotherapy, herpes virus, human papillomavirus

Abstract

Relevance. Chronic persistent viral infections are a category of andro-urological problems that currently have no defi nite solutions.
The aim of the study is to evaluate the eff ectiveness of treatment of chronic infl ammatory diseases
of the prostate gland (persistent viral mixed infections: combinations of herpes simplex virus (first and second types) and human papilloma virus using the drug “Allokin-alpha”(Alloferonum)), in comparison with recombinant human interferon-2b.
Materials and methods. The study was conducted on a contingent of 60 patients of the clinic “Men’s Health”, Kyiv. The study design suggested the use of 2 parallel groups of 30 patients receiving treatment according to diff erent therapeutic models.
The results of the study. When comparing therapeutic models using parenteral administration of Alloferonum in the composition of the drug “Allokin-alpha” and parenteral administration of recombinant human interferon-2b in parallel groups of patients suff ering from chronic persistent mixed infections, a number of diff erences regarding serological and clinical effi cacy and long-term eff ects were found.
Findings. The eff ectiveness of the elimination of chronic persistent viral mixed infections for Alloferonum was 66,7%, for recombinant human interferon-2b in - 40%. The catamnestic eff ects of therapeutic models also diff ered. For Alloferonum 6 months after the course of treatment, the recovery of serological activity of viruses occurred in 13,4% of patients, the return of systemic clinical manifestations was observed in 23,3% of patients, the return of symptoms of specifi c prostatitis - in 10,0% of patients. For recombinant human interferon-2b, similar fi gures were 23,0%, 33,3% and 20,0%, respectively.

Published
2019-08-28
How to Cite
Заседа, Ю., Соломенный, Р., & Шихалиев, Ф. (2019). THE EXPERIENCE OF THE USE OF ALLOKINE-ALPHA IN TREATMENT OF CHRONIC PERSISTING VIRAL MIXT-INFECTIONS IN MEN. Men’s Health, Gender and Psychosomatic Medicine, (1), 25-32. https://doi.org/10.37321/UJMH.2019.01-02

Most read articles by the same author(s)